Notably, it is possible to recognize two different CRC subtypes on the basis of BRAF V600E: BRAF mutant 1 (BM1), associated with activation of K-RAS/AKT pathway, dysregulation of mTOR/4EBP, and activation of epithelial to mesenchymal transition (EMT); BRAF mutant 2 (BM2) is distinguished by dysregulation of the cell cycle checkpoints, so it exhibits low levels of cyclin D1 (CD1) but increased CD1-kynase (CDK1) levels [69]. This evidence concerns the gene BRAF and colorectal carcinoma.